Document:

krys-20201231ex43_descri

Exhibit 4.3  DESCRIPTION OF COMMON STOCK  General  Our authorized capital stock consists of 80,000,000 shares of common stock, $0.00001 par value per share,  and 20,000,000 shares of preferred stock, $0.00001 par value per share. Our common stock is registered under  Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have no other  securities registered under Section 12 of the Exchange Act.   The following description summarizes the most important terms of our common stock. Because it is only a  summary, it does not contain all the information that may be important to you. The description is intended as a  summary, and is qualified in its entirety by reference to our second amended and restated certificate of incorporation  (our “Certificate of Incorporation”) and our amended and restated bylaws (our “Bylaws”). For a complete  description, you should refer to our Certificate of Incorporation and Bylaws.  Common Stock  Dividend Rights  The holders of our common stock are entitled to receive dividends out of funds legally available if our  board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that  our board of directors may determine.   Voting Rights  Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote  of stockholders. We have not provided for cumulative voting for the election of directors in our Certificate of  Incorporation. Accordingly, holders of a majority of the shares of our common stock will be able to elect all of our  directors. Our Certificate of Incorporation has established a classified board of directors, divided into three classes  with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our  stockholders, with the other classes continuing for the remainder of their respective three-year terms.  No Preemptive or Similar Rights  Our common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or  sinking fund provisions.  Right to Receive Liquidation Distributions  Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our  stockholders would be distributable ratably among the holders of our common stock at that time, subject to prior  satisfaction of all outstanding debt and liabilities.  Anti-Takeover Provisions  The provisions of Delaware law, our Certificate of Incorporation and our Bylaws could have the effect of  delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which  are summarized below, may have the effect of discouraging takeover bids. They are also designed, in part, to  encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the  benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer  outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could  result in an improvement of their terms.  

 

Delaware Law  We are subject to the provisions of Section 203 of the Delaware General Corporation Law (the “DGCL”),  regulating corporate takeovers. In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation  from engaging in a business combination with an interested stockholder for a period of three years following the  date on which the person became an interested stockholder unless:  • prior to the date of the transaction, the board of directors of the corporation approved either the  business combination or the transaction which resulted in the stockholder becoming an interested  stockholder;   • the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the  time the transaction commenced, excluding for purposes of determining the voting stock outstanding,  but not the outstanding voting stock owned by the interested stockholder: (i) shares owned by persons  who are directors and also officers; and (ii) shares owned by employee stock plans in which employee  participants do not have the right to determine confidentially whether shares held subject to the plan  will be tendered in a tender or exchange offer; or   • at or subsequent to the date of the transaction, the business combination is approved by the board of  directors of the corporation and authorized at an annual or special meeting of stockholders, and not by  written consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not  owned by the interested stockholder.   Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of  transactions together resulting in a financial benefit to the interested stockholder. An interested stockholder is a  person who, together with affiliates and associates, owns or, within three years prior to the determination of  interested stockholder status, did own 15% or more of a corporation’s outstanding voting stock. We expect the  existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not  approve in advance. We also anticipate that Section 203 of the DGCL may also discourage attempts that might result  in a premium over the market price for the shares of common stock held by stockholders.  Second Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws  Provisions  Our Certificate of Incorporation and our Bylaws include a number of provisions that could deter hostile  takeovers or delay or prevent changes in control of our company, including the following:  • Board of Directors Vacancies. Our Certificate of Incorporation and Bylaws authorizes only our board  of directors to fill vacant directorships, including newly created seats. In addition, the number of  directors constituting our board of directors may only be set by a resolution adopted by a majority vote  of our entire board of directors. These provisions would prevent a stockholder from increasing the size  of our board of directors and then gaining control of our board of directors by filling the resulting  vacancies with its own nominees. This makes it more difficult to change the composition of our board  of directors but promotes continuity of management.   • Classified Board. Our Certificate of Incorporation and Bylaws provide that our board of directors will  be classified into three classes of directors, each with staggered three-year terms. A third party may be  discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more  difficult and time consuming for stockholders to replace a majority of the directors on a classified  board of directors.  Stockholder Action; Special Meetings of Stockholders. Our Certificate of Incorporation provides that  our stockholders may not take action by written consent, but may only take action at annual or special  meetings of our stockholders. As a result, a holder controlling a majority of our capital stock may not  amend our restated bylaws or remove directors without holding a meeting of our stockholders called in  accordance with our restated bylaws. Further, our Certificate of Incorporation and Bylaws provide that  

 

special meetings of our stockholders may be called only by a majority of our board of directors, the  chairman of our board of directors, or our Chief Executive Officer, thus prohibiting a stockholder from  calling a special meeting. These provisions might delay the ability of our stockholders to force  consideration of a proposal or for stockholders controlling a majority of our capital stock to take any  action, including the removal of directors.   • Advance Notice Requirements for Stockholder Proposals and Director Nominations. Our Bylaws  provides advance notice procedures for stockholders seeking to bring business before our annual  meeting of stockholders or to nominate candidates for election as directors at our annual meeting of  stockholders. Our Bylaws also specifies certain requirements regarding the form and content of a  stockholder’s notice. These provisions may preclude our stockholders from bringing matters before our  annual meeting of stockholders or from making nominations for directors at our annual meeting of  stockholders if the proper procedures are not followed. We expect that these provisions may also  discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s  own slate of directors or otherwise attempting to obtain control of our company.   • No Cumulative Voting. The DGCL provides that stockholders are not entitled to the right to cumulate  votes in the election of directors unless a corporation’s certificate of incorporation provides otherwise.  Our Certificate of Incorporation does not provide for cumulative voting.   • Directors Removed Only for Cause. Our Certificate of Incorporation provides that stockholders may  remove directors only for cause and only by the affirmative vote of the holders of at least two-thirds of  our outstanding common stock.   • Amendment of Charter Provisions. Any amendment of the above expected provisions in our Certificate  of Incorporation requires approval by holders of at least two-thirds of our outstanding common stock.   • Issuance of Undesignated Preferred Stock. Our board of directors has the authority, without further  action by the stockholders, to issue up to 20,000,000 shares of undesignated preferred stock with rights  and preferences, including voting rights, designated from time to time by our board of directors. The  existence of authorized but unissued shares of preferred stock will enable our board of directors to  render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender  offer, proxy contest or other means.   • Choice of Forum. Our Certificate of Incorporation provides that the Court of Chancery of the State of  Delaware will be the exclusive forum for: any derivative action or proceeding brought on our behalf;  any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant  to the DGCL, our Certificate of Incorporation or our Bylaws; any action to interpret, apply, enforce or  determine the validity of our Certificate of Incorporation or our Bylaws; or any action asserting a claim  against us that is governed by the internal affairs doctrine. The enforceability of similar choice of  forum provisions in other companies’ certificates of incorporation has been challenged in legal  proceedings, and it is possible that a court could find these types of provisions to be inapplicable or  unenforceable.   Transfer Agent and Registrar  The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer  agent’s address is Meidinger Tower, 462 S. 4th Street, Louisville, KY 40202, and its telephone number is 1-502-601- 6000. Our shares of common stock were issued in uncertificated form only, subject to limited circumstances.  NASDAQ Capital Market Listing  Our common stock is listed on The NASDAQ Capital Market under the symbol “KRYS.”krys-20201231ex104_emplo

                                                                                          Exhibit 10.4        sf-3750204KBca       E M P L O Y M E N T  A G R E E M E N T   This Employment Agreement (“the Agreement”), dated November 22, 2019, is  between Krystal Biotech, Inc., a Delaware corporation (the “Company”) and Kathryn  Romano (“Employee”) and reflects the Company’s and Employee’s desire to establish a  full employment relationship.  1.  POSITION AND RESPONSIBILITIES  a. Position.  Employee is employed by the Company to render services to  the Company in the position of Chief Accounting Officer, commencing January 20,  2020 (“Start Date”). Employee shall perform such duties and responsibilities as are  normally related to such position in accordance with the standards of the industry and  any additional duties now or hereafter assigned to Employee by the Chief Executive  Officer, to whom Employee shall report. Employee shall abide by the rules,  regulations, and practices as adopted or modified from time to time in the Company’s  sole discretion. Employee’s primary location shall be in Pittsburgh, PA. This  employment offer is contingent upon the completion of a satisfactory reference check,  background check and drug screen.   b. Other Activities.  Except with the prior written consent of the Company,  Employee will not, during the term of Employee’s employment with the Company, (i)  accept any other employment, or (ii) engage, directly or indirectly, in any other  business activity (whether or not pursued for pecuniary advantage) that might  interfere with Employee’s duties and responsibilities hereunder or create a conflict of  interest with the Company.  c. No Conflict.  Employee represents and warrants that Employee’s  execution of this Agreement, Employee’s employment with the Company, and the  performance of Employee’s proposed duties under this Agreement shall not violate any  obligations Employee may have to any other employer, person or entity, including any  obligations with respect to proprietary or confidential information of any other person  or entity.  2.  COMPENSATION AND BENEFITS  a. Base Salary and Bonus.  In consideration of the services to be rendered  under this Agreement, the Company shall pay Employee a base salary at the rate of  

 

   2  sf-3750204 KBca  TWO HUNDRED THOUSAND DOLLARS ($200,000) per year (“Base Salary”) plus an   additional annual target bonus of up to 40%, subject to meeting corporate and  individual goals.   b. The Base Salary shall be paid in accordance with the Company’s regularly  established payroll practice.    c. Employee’s Base Salary will be reviewed from time to time in accordance  with the established procedures of the Company for adjusting salaries for similarly  situated employees and may be increased in the sole discretion of the Company.   d. Stock Options. The Employee will be provided with an option to purchase  50,000 shares of the Common Stock of the Company (the “Option”), as adjusted by  any stock splits that may occur. The exercise price per share of the shares subject to  the Option shall be determined in a manner compliant with Section 409A of the  Internal Revenue Code, to be the closing price of the Company’s common stock as  quoted on NASDAQ on January 31, 2020 or, if the Start Date shall not occur prior to  January 31, 2020, then the closing price of the Company’s common stock as quoted  on NASDAQ on the last day of the calendar month during which the Start Date occurs.    Employee’s entitlement to such stock options is conditioned upon Employee’s signing  of an Option Agreement in the form attached hereto, between the Company and the  Employee (the “Option Agreement”) and is subject to the terms of the Option  Agreement and of the Krystal Biotech, Inc. 2017 IPO Stock Incentive Plan (the “Plan”).  The Option shall vest with respect to 25% of the Shares subject thereto on the first  (1st) anniversary of the Start Date. The remaining unvested portion of the Option shall  vest 25% on each of the next three (3) anniversaries of the Start Date such that on  the fourth (4th) anniversary of the Start Date, Employee shall be fully vested in the  Option; subject to the Continuous Service of Employee continuing on each such  vesting date in order to vest in the applicable portion of the Option. Any vested Option  shall be eligible for Early Exercise (as defined under the Plan) provided, however, that  such Early Exercise shall be conducted in accordance with Section 7 of the Plan.  Notwithstanding anything herein to the contrary, in the event of a Corporation  Transaction (as defined in the Plan), the vesting of Employee’s then outstanding  unvested equity awards, including the Option and any other Award (as defined in the  Plan), shall accelerate as of immediately prior to such a Corporation Transaction (and,  if applicable, all restrictions and rights of repurchase on such awards shall lapse).  e. Benefits.  Employee, at a minimum, shall be eligible to participate in the  benefits made generally available by the Company to similarly-situated employees, in  accordance with the benefit plans established by the Company, and as may be  amended from time to time at the Company’s sole discretion.  

 

   3  sf-3750204 KBca  f. Expenses.  The Company shall reimburse Employee for reasonable  business expenses incurred in the performance of Employee’s duties hereunder in  accordance with the Company’s expense reimbursement guidelines.  3.  AT-WILL EMPLOYMENT; TERMINATION BY COMPANY  a. At-Will Termination by Company.  The employment of Employee shall  be “at-will” at all times. The Company may terminate Employee’s employment with  the Company at any time, without any advance notice, for any reason or no reason at  all notwithstanding anything to the contrary contained in or arising from any  statements, policies or practices of the Company relating to the employment,  discipline or termination of its employees.   In the event of any such termination by  the Company for any reason other than Cause, the Company shall pay to Employee an  amount equal to four weeks of her then-current Base Salary, which payment may, at  the request of the Company, be conditioned upon Employee’s execution of a usual and  customary general release in favor of the Company.  For the purposes of this  Agreement, “Cause” shall have the meaning provided in the Plan.    4.  AT-WILL EMPLOYMENT; TERMINATION BY EMPLOYEE  a. At-Will Termination by Employee.  Employee may terminate  employment with the Company at any time for any reason or no reason at all, upon  thirty days’ advance written notice. During such notice period Employee shall continue  to diligently perform all of Employee’s duties hereunder. The Company shall have the  option, in its sole discretion, to make Employee’s termination effective at any time  prior to the end of such notice period as long as the Company pays Employee all  compensation to which Employee is entitled up through the last day of the thirty-day  notice period.  5.  TERMINATION OBLIGATIONS  a. Return of Property.  Employee agrees that all property (including  without limitation all equipment, tangible proprietary information, documents, records,  notes, contracts and computer-generated materials) furnished to or created or  prepared by Employee incident to Employee’s employment belongs to the Company  and shall be promptly returned to the Company upon termination of Employee’s  employment.  b. Resignation and Cooperation.  Following any termination of  employment, Employee shall cooperate with the Company in the winding up of  pending work on behalf of the Company and the orderly transfer of work to other  employees. Employee shall also cooperate with the Company in the defense of any  

 

   4  sf-3750204 KBca  action brought by any third party against the Company that relates to Employee’s  employment by the Company.  c. Continuing Obligations.  Employee understands and agrees that  Employee’s obligations under Sections 5 and 6 herein (including Exhibit A) shall  survive the termination of Employee’s employment for any reason and the termination  of this Agreement.   6.  INVENTIONS AND PROPRIETARY INFORMATION; PROHIBITION ON  THIRD PARTY INFORMATION  a. Proprietary Information Agreement.  Employee agrees to sign and be  bound by the terms of the Company’s Proprietary Information and Inventions  Agreement, which is attached as Exhibit A (“Proprietary Information Agreement”).  b. Non-Disclosure of Third Party Information.  Employee represents and  warrants and covenants that Employee shall not disclose to the Company, or use, or  induce the Company to use, any proprietary information or trade secrets of others at  any time, including but not limited to any proprietary information or trade secrets of  any former employer, if any; and Employee acknowledges and agrees that any  violation of this provision shall be grounds for Employee’s immediate termination.  Employee further specifically and expressly acknowledges that no officer or other  employee or representative of the Company has requested or instructed Employee to  disclose or use any such third party proprietary information or trade secrets.  c. Noncompetition. In consideration of the Company’s extension to  Employee of full time employment with the Company, the Employee agrees that at no  time during the Employee’s employment with the Company, and for a period of one  (1) year immediately following the termination of such employment (regardless of the  reason for or the party initiating the termination), the Employee will not, directly or  indirectly, on the Employee’s own behalf or on behalf of any third party, in any  capacity (whether as a proprietor, stockholder, partner, officer, employee, consultant,  contractor, or otherwise), work for, be a consultant for, be employed by, or provide  strategic advice to any Competitor, where the services the Employee would render to  the Competitor are similar to those which the Employee performed for the Company.  As used herein, Competitor means any person or entity that both (a) is engaged in the  development of products or technologies which may compete with the products or  technologies under development by the Company at the time of Employee’s  termination or within the twelve (12) month period of Employee’s employment with  the Company immediately preceding such termination; and (b) is located within the  territory of the United States. This provision does not apply to (1) the Employees’  passive ownership of not more than 2% of the outstanding, publicly traded securities  of another company; or (2) work in a capacity that is unrelated to development or of  

 

   5  sf-3750204 KBca  products or technologies which may compete with those under development by the  Company.  7.  AMENDMENTS; WAIVERS; REMEDIES  This Agreement may not be amended or waived except by a writing signed by  Employee and by a duly authorized officer of the Company.  Failure to exercise any  right under this Agreement shall not constitute a waiver of such right.  Any waiver of  any breach of this Agreement shall not operate as a waiver of any subsequent  breaches.  All rights or remedies specified for a party herein shall be cumulative and in  addition to all other rights and remedies of the party hereunder or under applicable  law.  8.  ASSIGNMENT; BINDING EFFECT  a. Assignment.  The performance of Employee is personal hereunder, and  Employee agrees that Employee shall have no right to assign and shall not assign or  purport to assign any rights or obligations under this Agreement. This Agreement may  be assigned or transferred by the Company, including in connection with any  conversion of the Company into corporate form; and nothing in this Agreement shall  prevent the consolidation, merger or sale of the Company or a sale of any or all or  substantially all of its assets.   b. Binding Effect.  Subject to the foregoing restriction on assignment by  Employee, this Agreement shall inure to the benefit of and be binding upon each of the  parties; the affiliates, officers, directors, agents, successors and assigns of the  Company; and the heirs, devisees, spouses, legal representatives and successors of  Employee.  9.  NOTICES  All notices or other communications required or permitted hereunder shall be made in  writing and shall be deemed to have been duly given if delivered: (a) by hand; (b) by  a nationally recognized overnight courier service; or (c) by United States first class  registered or certified mail, return receipt requested, to the principal address of the  other party, as set forth below. The date of notice shall be deemed to be the earlier of  (i) actual receipt of notice by any permitted means, or (ii) five business days following  dispatch by overnight delivery service or the United States Mail. Employee shall be  obligated to notify the Company in writing of any change in Employee’s address.  Notice of change of address shall be effective only when done in accordance with this  paragraph.   

 

   6  sf-3750204 KBca  Company’s Notice Address:  Krystal Biotech, Inc.  2100 Wharton Street, Suite 701  Pittsburgh, PA 15203  Attention: Josh Suskin  Email: jsuskin@krystalbio.com    Employee’s Contact Information:  Kathryn Romano  848 Bebout Rd.  Venetia, PA 15367  412-491-9159  Kate.romano@yahoo.com                                                          10.  SEVERABILITY  If any provision of this Agreement shall be held by a court or arbitrator to be invalid,  unenforceable, or void, such provision shall be enforced to the fullest extent permitted  by law, and the remainder of this Agreement shall remain in full force and effect. In  the event that the time period or scope of any provision is declared by a court or  arbitrator of competent jurisdiction to exceed the maximum time period or scope that  such court or arbitrator deems enforceable, then such court or arbitrator shall reduce  the time period or scope to the maximum time period or scope permitted by law.   10.  TAXES  All amounts paid under this Agreement shall be paid less all applicable state and  federal tax withholdings and any other withholdings required by any applicable  jurisdiction or authorized by Employee.  Such witholdings shall not apply to any capital  gains or similar income resulting from any stock options or similar provisions.  11.  GOVERNING LAW AND JURISDICTION  This Agreement shall be governed by and construed in accordance with the laws of the  Commonwealth of Pennsylvania without regard to the conflict of law principles. Parties  agree to first try to mediate any conflict arising under this Agreement or a matter  related thereto. If such a conflict cannot be resolved through mediation then any suit  or action shall be brought in an appropriate federal or state court located in Allegheny  County, Pennsylvania.   

 

   7  sf-3750204 KBca  12.  INTERPRETATION  This Agreement shall be construed as a whole, according to its fair meaning, and not  in favor of or against any party. Sections and section headings contained in this  Agreement are for reference purposes only, and shall not affect in any manner the  meaning or interpretation of this Agreement. Whenever the context requires,  references to the singular shall include the plural and the plural the singular.   13.  COUNTERPARTS  This Agreement may be executed in any number of counterparts, each of which shall  be deemed an original of this Agreement, but all of which together shall constitute one  and the same instrument.   14.  AUTHORITY  Each party represents and warrants that such party has the right, power and authority  to enter into and execute this Agreement and to perform and discharge all of the  obligations hereunder; and that this Agreement constitutes the valid and legally  binding agreement and obligation of such party and is enforceable in accordance with  its terms.   15.  ENTIRE AGREEMENT  This Agreement is intended to be the final, complete, and exclusive statement of the  terms of Employee’s employment by the Company and may not be contradicted by  evidence of any prior or contemporaneous statements or agreements, except for  agreements specifically referenced herein (including the Employee Proprietary  Information and Inventions Agreement attached as Exhibit A and the Plan and the  Option Agreement). To the extent that the practices, policies or procedures of the  Company, now or in the future, apply to Employee and are inconsistent with the terms  of this Agreement, the provisions of this Agreement shall control. Any subsequent  change in Employee’s duties, position, or compensation will not affect the validity or  scope of this Agreement.   16.  EMPLOYEE ACKNOWLEDGEMENT  Employee acknowledges Employee has had the opportunity to consult legal  counsel concerning this agreement, that Employee has read and understands  the agreement, that Employee is fully aware of its legal effect, and that  Employee has entered into it freely based on Employee’s own judgment and  

 

   8  sf-3750204 KBca  not on any representations or promises other than those contained in this  agreement.  IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date  first written above.   KRYSTAL BIOTECH, INC. Kathryn Romano  By:  _________________________________   ________________________     Josh Suskin   Name  Title:  Director of Human Resources   Employee

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]